Library — CHDR

Search

Filter

A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis.

Liu F, Aulin LBS, Kossen SSA, Cathalina J, Bremmer M, Foks AC, van der Graaf PH, Moerland M, van Hasselt JGC

Journal of pharmacokinetics and pharmacodynamics, 2022 Oct

View publication
Monitoring of Ex vivo Cyclosporin A Activity in Healthy Volunteers Using T Cell Function Assays in Relation to Whole Blood and Cellular Pharmacokinetics

Aliede E. in ’t Veld, Manon A. A. Jansen, Bertine W. Huisman, Mascha Schoonakker, Marieke L. de Kam, Dirk Jan A. R. Moes, Mariëtte I. E. van Poelgeest, Jacobus Burggraaf and Matthijss Moerland

Pharmaceutics, 2022 Sep

View publication
Characterization of KLH-driven immune responses in clinical studies: A systematic review

Mahdi Saghari, Manon A. A. Jansen, Hendrika W. Grievink, Robert Rissmann, Matthijs Moerland

Front. Drug. Discov, 2022 Sep

View publication
A randomized controlled trial with a delayed-type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man.

Saghari M, Gal P, Ziagkos D, Burggraaf J, Powell JF, Brennan N, Rissmann R, van Doorn MBA, Moerland M

British journal of clinical pharmacology, 2020 Oct

View publication
Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients.

van Meir H, Nout RA, Welters MJ, Loof NM, de Kam ML, van Ham JJ, Samuels S, Kenter GG, Cohen AF, Melief CJ, Burggraaf J, van Poelgeest MI, van der Burg SH

Oncoimmunology, 2017 Aug; 6(2):e1267095

View publication
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.

Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf J, Melief CJ, van der Burg SH

Science translational medicine, 2016 Apr; 8(334):334ra52

View publication
The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.

van Meir H, Kenter GG, Burggraaf J, Kroep JR, Welters MJ, Melief CJ, van der Burg SH, van Poelgeest MI

Anti-cancer agents in medicinal chemistry, 2014 Jan; 14(2):190-203

View publication